Biopsy tissue expresses the complement C5a receptor 1 and the leukotriene LTB4 receptor BLT1 on and within the surface of the eye, a previously …
Akari Therapeutics Announces Positive Phase II Clinical Data in Orphan Blistering Skin Disease Bullous Pemphigoid at the 28th EADV Congress
Treatment with nomacopan in six patients in Phase II trial was well tolerated and resulted in rapid onset of clinical improvement in five of six patientsNo …
Akari Therapeutics to Participate in Ladenburg Thalmann Healthcare Conference
NEW YORK and LONDON, September 18, 2019 – Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan …
[Read more...] about Akari Therapeutics to Participate in Ladenburg Thalmann Healthcare Conference
Akari Therapeutics’ Nomacopan Granted U.S. Orphan Drug Designation for Bullous Pemphigoid
NEW YORK and LONDON, September 13, 2019 – Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan …
Akari Therapeutics to Participate in Citi and H.C. Wainwright Conferences in Early September
NEW YORK and LONDON, September 3, 2019 – Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan …
